Sensorion (ALSEN) Corporate Presentation summary

Vision and strategy

• Aims to help people with inner ear hearing disorders live with unlimited connections.

• Focuses on treating, preventing, and restoring hearing in areas of high unmet clinical need.

• Employs a modality-agnostic approach, leveraging gene therapies and small molecules.

• Combines internal capabilities with exclusive global partnerships, including Institut Pasteur and Cochlear.

• Listed on Euronext Growth with a €170M market cap and €77M cash as of Dec 31, 2024, providing runway until end of Q1 2026.

Leadership and partnerships

• Led by experienced executives from major pharma and biotech companies.

• Board includes representatives from leading life sciences investors and independent directors.

• Scientific Advisory Board features renowned experts in genetics and hearing research.

• Collaborates with global clinical centers of excellence and industry leaders like Sonova and Cochlear.

Pipeline overview

• Diversified pipeline includes gene therapies (SENS-501, GJB2-GT) and small molecule SENS-401.

• Multiple indications targeted: otoferlin deficiency, GJB2-related hearing loss, hearing preservation post-cochlear implant, cisplatin-induced ototoxicity, and sudden sensorineural hearing loss (SSNHL).

• Several clinical milestones expected in 2025 and 2026.